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https://doi.org/10.1016/j.celrep.2020.107697SUMMARYThe transmembrane sodium-calcium (Na-Ca) exchanger 1 (NCX1) regulates cytoplasmic Ca levels by facili-
tating electrogenic exchange of Ca for Na. Palmitoylation, the only reversible post-translational modification
known to modulate NCX1 activity, controls NCX1 inactivation. Here, we show that palmitoylation of NCX1
modifies the structural arrangement of the NCX1 dimer and controls its affinity for lipid-ordered membrane
domains. NCX1 palmitoylation occurs dynamically at the cell surface under the control of the enzymes
zDHHC5 and APT1. We identify the position of the endogenous exchange inhibitory peptide (XIP) binding
site within the NCX1 regulatory intracellular loop and demonstrate that palmitoylation controls the ability
of XIP to bind this site. We also show that changes in NCX1 palmitoylation change cytosolic Ca. Our results
thus demonstrate the broad molecular consequences of NCX1 palmitoylation and highlight a means to
manipulate the inactivation of this ubiquitous ion transporter that could ameliorate pathologies linked to
Ca overload via NCX1.INTRODUCTION
The sodium-calcium (Na-Ca) exchanger 1 (NCX1) regulates
intracellular Na and Ca by facilitating the bidirectional transport
of Ca under the control of the transmembrane Na gradient in
excitable and non-excitable cells. In cardiac muscle, for
example, NCX1 activity is an important determinant of ventricu-
lar filling, but it also indirectly controls systolic function by
competing with the enzyme responsible for intracellular Ca stor-
age, SERCA2a (Ottolia et al., 2013). Inappropriate NCX1 activity
contributes to numerous cardiac pathologies, including myocar-
dial infarction (Ohtsuka et al., 2004), heart failure (Flesch et al.,
1996), and arrhythmias (Dai et al., 2019; Voigt et al., 2012).
NCX1 is a functional dimer (John et al., 2011; Ren et al., 2008)
that is allosterically regulated by both ions it transports through
effects on its large regulatory intracellular loop (f-loop). Elevated
intracellular Na inactivates NCX1 (Hilgemann et al., 1992), but the
identity of the regulatory Na binding site responsible for this inac-
tivation is not known. The binding of Ca at two Ca-binding do-
mains (CBDs) counteracts this inhibition and activates NCX1 (Ot-
tolia et al., 2009). Binding of 4 Ca ions to CBD1, the high-affinity
Ca -binding site (Kd 0.2 mM), activates NCX1; binding of 2 Ca
ions to CBD2, a lower-affinity site (Kd 10 mM), opposes NCX1
inactivation (Khananshvili, 2020). Structural information to
explain how allosteric regulation via occupancy of the CBDs isThis is an open access article undtranslated into functional effects on ion transport remains poorly
understood, as the only exchanger to have its structure solved
lacks allosteric regulatory sites (Liao et al., 2012, 2016).
The activities of numerous ion channels and transporters are
key to controlling the function of excitable tissues. Voltage-gated
channels, ion pumps, exchangers, and their accessory subunits
are all palmitoylated (Howie et al., 2013; Shipston, 2011), with
diverse functional consequences. Palmitoylation is the only
reversible post-translational modification reported to regulate
NCX1 (Fuller et al., 2016; Go¨k and Fuller, 2020; Reilly et al.,
2015). S-palmitoylation, the esterification of palmitate to
cysteine side chains, reversibly anchors intracellular regions of
proteins to membranes (Linder and Deschenes, 2007). Cata-
lyzed by zinc-finger- and DHHC-motif-containing palmitoyl
acyl transferases (zDHHC-PATs; Mitchell et al., 2006), and
reversed by thioesterases, this lipid modification regulates the
activity, stability, subcellular distribution, and lipid interactions
of peripheral and integral membrane proteins (Salaun et al.,
2010). Palmitoylation can control the affinity of proteins for mem-
branes based on their shape (Larsen et al., 2015); it directly influ-
ences membrane curvature (Chlanda et al., 2017) and promotes
the clustering and internalization of both proteins and lipids (Hil-
gemann et al., 2013). It is therefore important to understand the
control and cellular consequences of this post-translational
modification for protein structure and function.Cell Reports 31, 107697, June 9, 2020 ª 2020 The Authors. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Figure 1. Palmitoylation Modifies FRET between NCX1 Dimers
(A) Schematic of the NCX1 FRET sensors used in this investigation, indicating the positions of transmembrane (TM) domains, exchange inhibitory peptide (XIP),
FRET sensors (CFP and YFP), Ca binding domains (CBDs), and palmitoylation site.
(B) Palmitic acid (upper structure, at 20 mM, 4 h) supplementation increases the palmitoylation of endogenous NCX1 in neonatal rat ventricularmyocytes (NRVMs).
Western blots show abundance of NCX1 (upper) and the lipid raft resident protein flotillin 2 (loading control, lower) in unfractionated cell lysates (UF) and purified
palmitoylated fraction (HA). The bar chart (right) showsNCX1 palmitoylation (HA fraction) normalized to expression (UF) in treated (blue, +) relative to untreated ()
NRVMs (N = 5).
(legend continued on next page)
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OPEN ACCESSNCX1 is palmitoylated at a single cysteine at position 739 in
its f-loop, on the carboxyl terminal side of CBD2 (Fuller et al.,
2016; Go¨k and Fuller, 2020; Plain et al., 2017; Reilly et al.,
2015). Palmitoylation is required for NCX1 inactivation, which
is mediated by the interaction of the endogenous exchange
inhibitory peptide (XIP) with the f-loop. XIP inactivation of
NCX1 requires residues 562–679 (Maack et al., 2005; Matsuoka
et al., 1993), although this large region of the NCX1 f-loop in-
cludes part of CBD2 and it is likely that the core XIP-binding
site is smaller. The physiological importance of NCX1
inactivation has not yet been fully established. Inactivation likely
represents a means to tune NCX1 activity in response to mobi-
lization of PIP2 (which usually sequesters the XIP domain).
Furthermore, NCX1 inactivation plays an important role in
limiting NCX1-mediated Ca influx (and hence cellular injury) un-
der circumstances of Na overload, metabolic stress, or
acidosis (Hilgemann et al., 2006; Reeves and Condrescu,
2008).
Molecular recognition of the NCX1 palmitoylation site is facil-
itated by the presence of an amphipathic a-helix, which is posi-
tioned at the carboxyl terminal end of the f-loop (Plain et al.,
2017). However, how palmitoylation regulates NCX1 behavior
is only partially understood. Furthermore, it remains unknown
whether NCX1 palmitoylation is a one-off event, linked to its
passage through the secretory pathway, or a dynamic event
that occurs at the cell surface. Here, we investigated how pal-
mitoylation regulates the dimerization, lipid interactions, and
inactivation of NCX1 in HEK cells and ventricular myocytes
and report several important advances. Our findings show
that palmitoylation modifies both NCX1-NCX1 dimerization
and the ability of XIP to bind to and inactivate NCX1. We iden-
tify a region of the NCX1 f-loop adjacent to the NCX1 palmitoy-
lation site where XIP binds, which is distinct from the region of
the f-loop required for XIP to inactivate NCX1. We find that pal-
mitoylation of NCX1 at the cell surface is dynamic and that the
structural motif in the NCX1 f-loop that is required for NCX1
palmitoylation also recruits the thioesterase APT1. From our
findings, we propose that palmitoylation creates a site within
the NCX1 f-loop where XIP binds, thereby facilitating NCX1
inactivation while also controlling the protein’s affinity for lipid
rafts in the plasma membrane. The reduced sensitivity of
non-palmitoylated NCX1 to inactivation ultimately leads to
elevated intracellular Ca. Hence, the palmitoylation status of
NCX1 regulates cytosolic Ca.(C) NCX1-NCX1 FRETmeasurements in transiently transfected NRVMs. The imag
ratio was calculated as the ratio of background-subtracted YFP and CFP sig
(D) Palmitic acid supplementation (20 mM, 4 h) significantly enhances NCX1-NCX1
by unpaired t test. N = 14.
(E) Position of the NCX1 palmitoylation site. The magnified box shows the positi
(F) FT-293 cells that stably express tetracycline (Tet)-inducibleWTNCX1 treated w
In FT-293 cells that stably express Tet-inducible C739A NCX1, NCX1 is not p
expression, in 2-BP-treated (black) relative to untreated (gray) FT-293 cells. **p =
(G) An example of NCX1-NCX1 FRETmeasurements in transiently transfected HEK
4 h, middle), and C739A NCX1 (right). Scale bar, 10 mm.
(H) NCX1-NCX1 FRET activity is significantly reduced in HEK293 cells expressing
C739A NCX1. ****p < 0.0001, calculated by unpaired t test. N = 14 (WT), 14 (WT
(I) Cross-linking of NCX1 using 0.1 mM BMH. The NCX1 monomer migrates at ~
between palmitoylatable WT NCX1 and unpalmitoylatable C739A. N = 5 for WTRESULTS
Palmitoylation Increases NCX1-NCX1 FRET Signals in
Live Cells
Previously, NCX1 dimerization has been detected by performing
intermolecular fluorescence resonance energy transfer (FRET)
between CFP- and YFP-tagged NCX1 in plasma membrane
sheets prepared from Xenopus oocytes (John et al., 2011).
Here, we expressed full-length NCX1with the same fluorophores
inserted at position 266 (at the N-terminal end of the NCX1
f-loop; Figure 1A) in neonatal rat ventricular myocytes (NRVMs).
Palmitic acid supplementation of myocytes is known to enhance
the palmitoylation of certain cardiac proteins (Pei et al., 2016).
The treatment of NRVMs with palmitic acid increased both
endogenous NCX1 palmitoylation (Figure 1B) and NCX1-NCX1
FRET (Figures 1C and 1D). These palmitoylation-dependent
changes in NCX1 FRET behavior suggest that either (1) palmitoy-
lation regulates NCX1 dimerization or (2) palmitoylation restruc-
tures the f-loop in existing NCX1 dimers to promote intermolec-
ular FRET.
Next, we evaluated NCX1 FRET activity in HEK cells that ex-
pressed either wild-type (WT) or unpalmitoylatable (C739A)
NCX1 (Figures 1E and 1F). The FRET signal generated by unpal-
mitoylatable NCX1 was markedly reduced compared to that of
WT NCX1 (Figure 1G). Furthermore, the broad-spectrum
zDHHC-PAT inhibitor 2-bromopalmitate significantly reduced
both NCX1 palmitoylation and FRET between WT NCX1 dimers
(Figures 1G and 1H). In both cell types tested, NCX1 palmitoyla-
tion consistently caused an increase in NCX1-NCX1 FRET sig-
nals. The intensity of any FRET signal depends considerably
on the distance (1/r6) between donor and acceptor fluorophores.
The observed increase in NCX1-NCX1 FRET that occurs
following NCX1’s palmitoylation most likely reflects a reduction
in the distance between the two fluorophores. This, in turn, sug-
gests that the palmitoylation of the f-loop induces a discernible
conformational change within the cytoplasm-facing structure
of NCX1. To determine whether the change in NCX1-NCX1
FRET signal induced by palmitoylation reflected a conforma-
tional change in existing dimers or a difference in the propensity
of NCX1 to dimerize, FT-293 cells expressing eitherWT or unpal-
mitoylatable NCX1 were briefly treated with the homo-bifunc-
tional cross-linker bismaleimidohexane (BMH). The amount of
NCX1 dimer detected was essentially the same (Figure 1I). We
conclude that palmitoylation restructures existing NCX1 dimers.es show representative cells visualized in the CFP and YFP channels. The FRET
nals (scale bar, 10 mm).
FRET in treated (+) relative to untreated () NRVMs. ****p < 0.0001, calculated
on of the C739A mutation, which prevents the palmitoylation of NCX1.
ith 2-bromopalmitate (2-BP; 50 mM, 4 h) showed reducedNCX1 palmitoylation.
almitoylated. The bar chart (right) shows NCX1 palmitoylation normalized to
0.003, calculated by unpaired t test. N = 5.
293 cells expressingWTNCX1 (left),WTNCX1 in the presence of 2-BP (50 mM,
WT NCX1 and treated with 2-BP (50 mM, 4 h) and in HEK293 cells expressing
+2-BP), and 19 (C739A).
120 kDa and the dimer at ~250 kDa. The monomer/dimer ratio was identical
NCX1 and C739A.
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The affinity of single-transmembrane-domain proteins for lipid
rafts is regulated by palmitoylation (Lorent et al., 2017), and
numerous integral membrane proteins are palmitoylated and
reside in lipid rafts (Wypijewski et al., 2015). However, to date,
no multi-pass membrane domain protein has been found to
have a significant affinity for the raft phase formed in phase-
separated giant plasma membrane vesicles (GPMVs), which
are widely used to investigate membrane protein behaviors in
lipid raft and non-raft phases (Diaz-Rohrer et al., 2014; Levental
et al., 2010; Lorent et al., 2017; Sezgin et al., 2012). Here, we
investigated the effect of palmitoylation on the affinity of NCX1
for lipid rafts in intact cells and GPMVs. We treated HEK cells
with 5 mM methyl-b-cyclodextrin (MbCD) to disrupt membrane
rafts and with 25 mM SDS to enhance raft formation. MbCD re-
moves cholesterol from biological membranes, while low con-
centrations of detergents, such as SDS, enhance raft formation
in intact cells by increasing disorder in disordered microdomains
(Hilgemann et al., 2018; Zhou et al., 2013). Cells were stained
with filipin to confirm the successful depletion or clustering of
cholesterol following MbCD or SDS treatment (Figure 2A).
Enhancing raft formation with SDS significantly increased
NCX1-NCX1 FRET signals, but only when NCX1 was palmitoy-
latable (Figure 2B). The disruption of lipid rafts did not alter the
FRET signals produced by unpalmitoylatable NCX1, but it did
reduce FRET signals between WT NCX1 dimers such that they
were indistinguishable from that of unpalmitoylated NCX1 (Fig-
ure 2C). That the higher steady-state FRET between WT NCX1
dimers is sensitive to the destruction of lipid rafts suggests that
palmitoylation enhances the affinity of NCX1 for rafts. We
explored this possibility by visualizing the distribution of CFP-
tagged NCX1 in phase-separated GPMVs (Figure 2D). Unpalmi-
toylatable NCX1 partitioned entirely to the non-raft phase upon
phase separation. Interestingly, the presence of palmitoylated
WT NCX1 impaired the phase separation of GPMVs, which sug-
gests that palmitoylation of NCX1 fundamentally alters the
behavior of the membrane. WT NCX1 colocalized with both
raft and non-raft markers in GPMVs (Figure 2E), indicating that
palmitoylation does indeed control the affinity of NCX1 for lipid
rafts.
NCX1 Palmitoylation Creates an XIP Binding Site within
the f-Loop
NCX1 is inactivated when XIP (residues 219–238), located at the
N-terminal end of the NCX1 f-loop, interacts with a distal region
of the same loop (residues 562–679; Maack et al., 2005; Fig-
ure 3A). Palmitoylation enhances NCX1’s inactivation, but the
molecular basis of this process is only partially understood. We
investigated whether palmitoylationmodifies the relationship be-
tween XIP and NCX1, using a WT or mutant XIP peptide. The
point mutant XIP peptide we used cannot inactivate NCX1
(K229Q; Matsuoka et al., 1997). We also depleted PIP2 pharma-
cologically (Figure 3B), as PIP2 usually sequesters the endoge-
nous XIP domain to prevent NCX1 inactivation. We found that
biotinylated WT and K229Q XIP peptides could affinity purify
WT NCX1 from cell lysates with equal efficiency (Figure 3C),
which suggests that XIP engagement with and inactivation of
NCX1 are separate events. By fusing YFP to regions of the4 Cell Reports 31, 107697, June 9, 2020NCX1 f-loop (Plain et al., 2017), we probed the XIP binding site
in the f-loop (Figure 3D). Biotinylated XIP affinity purified NCX1
370–765, 501–765, 599–765, and surprisingly 690–765, which
does not include any part of the f-loop necessary for XIP to inac-
tivate NCX1 (Maack et al., 2005). Again, this emphasizes the sep-
aration of binding and efficacy in XIP inactivation of NCX1.
Next, we investigated the role of palmitoylation in regulating
XIP interaction with the NCX1 f-loop. Biotinylated XIP peptide
showed a substantially reduced ability to pull down unpalmitoy-
latable NCX1 following affinity purification (Figure 3E). This sug-
gests that NCX1 undergoes a conformational change on being
palmitoylated, which creates a binding site within the f-loop for
XIP. We sought to identify the location of this binding site by
probing an array of overlapping 25-mer peptides representing
NCX1 619–766 (covering the C-terminal half of CBD2 and the
linker between CBD2 and TMD6) with biotinylated XIP. We
took advantage of the fact that 15 mM, but not 5 mM, XIP binds
to the f-loop (Figure 3E) and classified peptides in the array inter-
acting with 5 mMXIP as false positives. Both 5 mMand 15 mMXIP
interacted with peptides representing the C-terminal end of
CBD2 (659–713, including the final Ca-coordinating residue,
E684). 15 mM XIP uniquely interacted with 25-mer peptides
covering 699–743, suggesting that the core XIP binding site is
a region immediately on the N-terminal side of the palmitoylation
site, 709-SWREQFIEAITVSAGEDDDD-728 (Figure 3F). We
therefore deleted this region from the NCX1 f-loop and tested
the impact on XIP binding. Since NCX1 palmitoylation effects
XIP binding, we first confirmed that palmitoylation of YFP-
NCX1 266–765 was unaffected by the mutation D709–728 (Fig-
ure 3G). Affinity purification of YFP-NCX1 266–765 by bio-
tinylated XIP peptide was largely abolished by the mutation
D709–728 (Figure 3H). Hence, we conclude that XIP interacts
with NCX1 709–728.
Since XIP is rich in basic amino acids, we reasoned that it
would cross the cell membrane in the same manner as reported
for other cell-penetrant polybasic peptides (Milletti, 2012). We
therefore investigated the impact on NCX1 FRET activity of
applying XIP to intact cells. WT, but not K229Q, XIP reduced
theWTNCX1 FRET signal; the FRET activity of unpalmitoylatable
NCX1 was modestly increased by XIP (Figure 3I). We depleted
PIP2 by activating phospholipase C with 3M3FBS in the pres-
ence of the phosphatidylinositol 3-kinase (PI3K) inhibitor wort-
mannin to prevent PIP2 resynthesis and then measured NCX
FRET. This pharmacological release of XIP from PIP2 also
reduced the FRET activity of WT NCX1 (Figure 3I). We concluded
from these results that the binding of XIP to NCX1 and NCX1
inactivation are independent events. XIP can bind to NCX1
regardless of whether or not it is capable of inactivating it
(XIP K229Q), but NCX1 needs to be palmitoylated to interact
with XIP with a high affinity.
NCX1 Depalmitoylation Pathways
Palmitoylation of NCX1 at C739 requires an amphipathic a-helix
(residues 740–756) located adjacent to this cysteine (Plain et al.,
2017). We reasoned that the zDHHC-PAT responsible for palmi-
toylating NCX1might interact with this helix. We therefore used a
peptide that represents NCX1 amino acids 740–756 and carries
an N-terminal biotin tag to affinity purify interacting proteins from
AB
C E
D
Figure 2. NCX1 Localization to Lipid Microdomains
(A) Visualization of cellular cholesterol with filipin in control (left), SDS-treated (center), and MbCD-treated (right) HEK293 cells (scale bar, 20 mm).
(B) Representative FRET images in HEK293 cells expressing WT (upper) and unpalmitoylatable (C739A, lower) NCX1 FRET sensors following treatment to
enhance (SDS) or reduce (MbCD) raft formation (scale bar, 10 mm).
(C) Mean FRET data. Enhancing raft formation increases NCX1-NCX1 FRET and reducing raft formation decreases NCX1-NCX1 FRET, but only when NCX1 is
palmitoylatable. ****p < 0.0001, calculated by unpaired t test. N = 14 (WT), 35 (WT+SDS), 16 (WT+MbCD), 19 (C739A), 26 (C739A+SDS), and 14 (C739A+MbCD).
(D) Schematic representation of giant plasma membrane vesicle (GPMV) phase separation and representative images displaying phase-separation behavior in
the presence of WT NCX1 (upper) and C739A NCX1 (lower). Scale bar, 2 mm.
(E) Colocalization analysis in phase-separated GPMVs. Left: increased colocalization of raft (CTxB-Alexa Fluor 647) and non-raft (FAST-DIL) markers in the
presence of WT versus C739A NCX1. Center: raft colocalization of WT and unpalmitoylatable NCX1. Right: non-raft colocalizaton of WT and unpalmitoylatable
NCX1. ****p < 0.0001, calculated by unpaired t test. N = 27 (WT) and 28 (C739A).
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OPEN ACCESSrat cardiac and brain lysates (Figure 4A). The interacting proteins
were then identified by liquid chromatography-tandem mass
spectrometry (LC-MS/MS) (Table S1). No zDHHC-PATs were
found to interact with this peptide. However, we did identify
the depalmitoylating enzyme APT1 (LYPLA1) from heart lysates.
We therefore investigated whether APT1 depalmitoylates NCX1.
The broad-spectrum thioesterase inhibitor palmostatin B
(PalmB; which inhibits ABHD isoforms as well as APT1; Lin and
Conibear, 2015) significantly enhanced both NCX1 palmitoyla-
tion and FRET between WT NCX1 dimers in HEK cells (Figures4B and 4C). The specific APT1 inhibitor ML348 (Adibekian
et al., 2012) also enhanced NCX1 palmitoylation and FRET, but
the APT2 inhibitor ML349 did not. PalmB and ML348, but not
ML349, also increased NCX1 palmitoylation in adult rabbit ven-
tricular myocytes (Figure 4B). None of these drugs significantly
influenced FRET between unpalmitoylatable NCX1 dimers (not
shown). These experiments show that the palmitoylation of
NCX1 is dynamic, with depalmitoylation depending on the activ-
ity of APT1, but not APT2. Our results therefore suggest
that APT1 is likely to be the enzyme that mediates NCX1Cell Reports 31, 107697, June 9, 2020 5
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Figure 3. Palmitoylation Enhances NCX1 XIP Affinity
(A) Schematic of the NCX1 intracellular f-loop, highlighting the position of XIP, CBDs, and the region of the f-loop required for XIP inactivation of NCX1 (562–679)
near the palmitoylation site.
(legend continued on next page)
6 Cell Reports 31, 107697, June 9, 2020
Article
ll
OPEN ACCESS
Article
ll
OPEN ACCESSdepalmitoylation. Moreover, the region of NCX1 required for its
palmitoylation may also be responsible for recruiting the NCX1
thioesterase.
NCX1 Palmitoylation Status and Cellular Environment
We investigated whether allosteric regulation by Na or Ca influ-
enced NCX1-NCX1 FRET by removing these ions from the extra-
cellular solution (Figure 5A). In Na-free solutions, NCX1-NCX1
FRET was substantially reduced, and in Ca-free solutions,
NCX1-NCX1 FRET was significantly increased (Figures 5B and
5C). Remarkably, these changes in FRET were not observed
when NCX1 was unpalmitoylatable, which suggests that they
are mediated by changes in NCX1 palmitoylation (Figures 5B
and 5C). Indeed, we found that Na-free solutions reduced and
Ca-free solutions enhanced NCX1 palmitoylation (Figure 5D).
These experiments provide additional support for NCX1 being
dynamically palmitoylated following its delivery to the cell sur-
face. They furthermore suggest that the NCX1 Ca-free (Na-
bound) structure is preferentially palmitoylated and the Na-free
(Ca-bound) structure is preferentially depalmitoylated.
zDHHC5 Palmitoylates NCX1 at the Cell Surface
The cell-surface zDHHC5-PAT recruits substrates via its
extended intracellular C tail (Howie et al., 2014). We used a li-
brary of overlapping biotinylated peptides, which represent the
first section of this C tail, to identify zDHHC5-binding proteins
in rat cardiac lysates and found that NCX1 interacts with
zDHHC5 (Figure 6A). To investigate a role for zDHHC5 in the pal-
mitoylation of NCX1, we generated zDHHC5 knockout (KO) cells
by transfecting FT-293 cells that express tetracycline-inducible
cas9 with a guide RNA targeting zDHHC5 (Munoz et al., 2014).
Successful gene targeting was confirmed by sequencing a re-
gion of PCR-amplified zDHHC5 exon 2 (bases 57,672,929 to
57,673,619 of Homo sapiens chromosome 11; the zDHHC5 initi-
ator methionine is the ATG in position 57,673,091). zDHHC5 pro-
tein was undetectable in lysates from KO cells (data not shown).
We first confirmed that zDHHC5 palmitoylates NCX1 by co-
expressing WT zDHHC5 or catalytically inactive zDHHS5 with
NCX1 in zDHHC5 KO cells (Figure 6B). FRET between WT
NCX1 dimers was substantially reduced in zDHHC5 KO
compared to WT HEK cells (Figures 6C and 6D). When zDHHC5(B) Schematic of the relationship between XIP and PIP2, highlighting the drugs (
(C) Biotinylated WT and inactive (K229Q) XIP peptides affinity purify YFP-tagged
(D) Biotinylated WT XIP peptides affinity purify YFP-tagged NCX1 f-loop region
fractionated cell lysate; XIP, proteins affinity purified by biotinylated XIP.
(E) Affinity purification of NCX1 from FT-293 cells expressing full-length NCX1 by a
reduced (2-BP) or abolished (C739A). Bar charts (right) show the amount of NCX
unfractionated cell lysate (UF). Statistical comparisons are between the relative
concentration of XIP (p values range from 0.04 [*] to 0.008 [**], N = 3). Inset: compar
BP-treated WT, or C739A NCX1-expressing cells. ****p < 0.0001, ***p = 0.0005 c
(F) Peptide array to map the XIP binding site in the NCX1 f-loop. Arrays of 25-m
centration of biotinylated XIP. The alignment alongside the arrays highlights the fin
(709-SWREQFIEAITVSAGEDDDD-728) in orange.
(G) Deletion of the putative XIP binding site (D709–728) has no impact on NCX1
(H) Deletion of residues 709–728 abolishes the interaction between the NCX1 f-l
(I) FRET activity of WT NCX1 is reduced by application of WT, but not K229Q XIP
unpalmitoylatable NCX1. ****p < 0.0001, ***p = 0.0006, *p = 0.034, calculated b
(WT+WMN+3-M3FBS 19 (C739A), and 16 (C739A+XIP).KO cells were exposed to Ca-free extracellular solutions, there
was no change in FRET between WT NCX1 dimers (Figures 6C
and 6D). This is therefore consistent with the notion that zDHHC5
is the ‘‘sensor’’ that mediates dynamic changes in NCX1 palmi-
toylation and FRET in different cellular environments.
NCX1 Palmitoylation and the Control of Intracellular Ca
To date, the impact of palmitoylation on NCX1 activity has been
defined using whole-cell voltage clamp following the dialysis of
intracellular contents. Given our finding that palmitoylation
changes XIP affinity of NCX1 and occurs dynamically at the
cell surface, we evaluated the impact of NCX1 palmitoylation
on intracellular Ca in intact FT-293 cells loaded with the Ca-sen-
sitive dye Fluo 4. Under physiological conditions (150 mM Na,
1.8 mM extracellular Ca, 10 mM Na, 100 nM intracellular Ca),
the reversal potential of NCX1 is 42 mV. In excitable tissues
(restingmembrane potential,80mV), NCX1-mediated Na influx
and Ca efflux occur at rest, but in HEK cells (resting membrane
potential, 24 mV; Kirkton and Bursac, 2011), NCX1 acts as a
Ca-influx pathway. Intracellular Ca was higher in the presence
of unpalmitoylatable NCX1 compared to WT NCX1 (Figure 7A).
This implies greater NCX-mediated Ca influx occurs when
NCX1 is not palmitoylated as a result of its reduced XIP sensi-
tivity. In separate experiments, increasing NCX1 palmitoylation
with PalmB reduced intracellular Ca in FT-293 cells expressing
WT NCX1 (Figure 7B), again suggesting that the palmitoylation
status of NCX1 controls intracellular Ca.
DISCUSSION
In this paper, we set out to investigate the cellular mechanisms
controlling NCX1 palmitoylation and the consequences of palmi-
toylation for NCX1 dimerization and lipid interactions, as well as
to understand the molecular basis of the requirement for palmi-
toylation for NCX1 to inactivate. Our findings show that the rela-
tionship between NCX1 and the lipid bilayer in which it resides is
fundamentally altered by palmitoylation. Our results show, for
the first time, that the palmitoylation of NCX1 at the cell surface
occurs dynamically under the control of APT1 and zDHHC5, with
the rates of palmitoylation and depalmitoylation influenced by
the NCX1 conformational poise. Palmitoylation increases FRETWMN and m-3M3FBS) used to manipulate PIP2 concentrations.
WT NCX1 f-loop equally efficiently from HEK cell lysates.
s 370–765, 501–765, 599–765, and 690–765 from HEK cell lysates. UF, un-
biotinylated XIP peptide is substantially reduced when NCX1 palmitoylation is
1 that co-purified with 5–100 mM XIP, relative to the abundance of NCX1 in the
amounts of WT, 2-BP-treated, and C739A NCX1 co-purified by a particular
ison of the amount of NCX1 binding to 25 mMXIP fromWT (defined as 100%), 2-
alculated by unpaired t test.
er peptides synthesized on membranes were probed with the indicated con-
al Ca coordinating residue of CBD2 (E684) in green and the core XIP binding site
palmitoylation (N = 4).
oop and XIP.
, or following depletion of PIP2. XIP modestly increases the FRET behavior of
y unpaired t test. N = 14 (WT), 8 (WT+K229Q), 12 (WT+XIP), 18 (DMSO), 18
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Figure 4. Identification of the NCX1 Depalmi-
toylating Enzyme
(A) Schematic of the affinity-purification reactions
that identified APT1 as a possible NCX1-interacting
protein.
(B) Impact of palmostatin B (PalmB; 20 mM), ML348
(APT1 inhibitor, 10 mM), and ML349 (APT2 inhibitor,
10 mM) on NCX1 palmitoylation in FT-293 cells sta-
bly expressing NCX1 (upper) and adult rabbit ven-
tricular myocytes (lower). All drugs were applied for
3 h before measurements. The bar charts show
NCX1 palmitoylation (HA fraction) normalized to
expression (UF) following the indicated treatments.
***p = 0.0003, **p = 0.0015 (FT-293) and 0.0036
(rabbit myocytes), *p = 0.0261, calculated by un-
paired t test. N = 7 (FT-293 cells), N = 7 (rabbit
myocytes).
(C) Impact of the same thioesterase inhibitors on
NCX1-NCX1 FRET. ****p < 0.0001, calculated by
unpaired t test. N = 14 (untreated), 18 (DMSO) 17
(PalmB), 15 (ML348), and 14 (ML349).
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OPEN ACCESSbetween protomers within an NCX1 dimer, enhances the affinity
of NCX1 for lipid-ordered domains at the cell surface, and is
required for XIP to bind to and inactivate NCX1. Ultimately, by
controlling the ability of NCX1 to inactivate, NCX1 palmitoylation
regulates cytosolic Ca.
XIP, Inactivation, and Control of Intracellular Ca by
NCX1 Palmitoylation
The functional effect of NCX1 palmitoylation is to modify NCX1
inactivation (Reilly et al., 2015). We have identified a region of
the f-loop adjacent to the palmitoylation site (residues 709–
728, enriched in negatively charged amino acids) that is required
for XIP binding to the f-loop. This is consistent with an electro-
static interaction between the polybasic XIP sequence and this
region of the f-loop being promoted by palmitoylation. We sug-
gest that by recruiting residues 709–728 close to the membrane,8 Cell Reports 31, 107697, June 9, 2020palmitoylation of C739 facilitates engage-
ment of this region with the XIP domain,
which is structurally constrained because
it is immediately adjacent to TM5 at the
N-terminal end of the f-loop. However,
since a soluble biotinylated XIP peptide af-
finity purifies unpalmitoylated NCX1 less
efficiently thanWT, the impact of palmitoy-
lation must also be to restructure the f-loop
to create a binding site for XIP in addition to
bringing this part of the protein closer to
the membrane.
The XIP docking site we have identified
lies only 15 amino acids on the C-terminal
side of CBD2. As the functional conse-
quence of Ca binding to CBD2 is the relief
of NCX1 inactivation, our investigation
suggests a scenario in which engagement
of XIP with its docking domain destabilizes
the Ca binding sites in CBD2 to promote
NCX1 inactivation. Considering the transi-tion from inactivated to activated state, Ca binding to CBD2
may reverse XIP binding and/or efficacy. As well as being impor-
tant for binding to 709–728, the polybasic nature of XIP may also
be important to disturb the co-ordination of Ca ions by acidic
residues in CBD2. Althoughwe have previously reported Ca acti-
vation of NCX1 is not changed by palmitoylation, we used Ca
concentrations that likely influence only the high-affinity binding
site CBD1 (Reilly et al., 2015). An important prediction arising
from this study that will be addressed in future experiments is
that bymodifying the ability of XIP to engage its docking site, pal-
mitoylation indirectly regulates the Ca affinity of CBD2 in full-
length NCX1.
How does NCX1 palmitoylation ultimately control intracellular
Ca? Our data indicate that NCX1-mediated transmembrane Ca
fluxes are reduced when NCX1 is palmitoylated and enhanced
when NCX1 is depalmitoylated, which implies that XIP tunes
AB C
D
Figure 5. NCX1 Palmitoylation and the Extra-
cellular Environment
(A) Schematic of the experimental intervention.
HEK293-expressing NCX1 FRET sensors were
incubated in Tyrode’s buffer (containing physio-
logical concentrations of Na and Ca) or modified
Tyrode’s buffer that was free of either Na (replaced
with NMDG) or Ca (chelated with 1 mM EGTA).
(B) An example of NCX1-NCX1 FRET measure-
ments in transiently transfected HEK293 cells ex-
pressing WT NCX1 (left, open circles) or un-
palmitoylatable NCX1 (right, closed circles) in
physiological (black), sodium-free (blue) and cal-
cium-free (red) conditions.
(C) Sodium-free (NaF) solutions reduce, and cal-
cium-free (CaF) solutions enhance, NCX1-NCX1
FRET, but only when NCX1 is palmitoylatable.
****p < 0.0001, *p = 0.01, calculated by unpaired t
test. Statistical comparisons in C739A groups are to
corresponding conditions forWTNCX1. N = 14 (WT,
Tyrode’s), 23 (WT, Na-free), 18 (WT, Ca-free), 19
(C739A Tyrode’s), 24 (C739A Na-free), 9 (C739A,
Ca-free).
(D) The same Na-free solutions reduce, and Ca-free
solutions enhance, NCX1 palmitoylation. UF, un-
fractionated lysate; HA, purified palmitoylated
fraction. The bar chart (right) shows NCX1 palmi-
toylation (HA fraction) normalized to expression (UF)
following the indicated treatments.
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OPEN ACCESSNCX1 activity at rest and not simply following PIP2 mobilization.
NCX1 inactivation is demonstrated to have a physiological role in
the control of intracellular Ca by our experiments. Clearly NCX1
palmitoylation modifies XIP binding, but destabilization of Ca
binding to CBD2 by XIP does not fully explain the NCX1 inactiva-
tion process. Although allosteric regulation by Na, Ca, and XIP
are lost, the proteolytic removal of the entire NCX1 f-loop does
not abolish exchanger activity, so CBD1, CBD2, and XIP are
not required for ion transport (Hilgemann, 1990; Philipson
et al., 1988). What is required for transporter activity, however,
is the entry of ions into their transmembrane binding sites along
extracellular and cytosolic vestibules. The complete cessation of
transporter activity that occurs when XIP binds to its docking site
could be explained if XIP binding prevented these ions from ac-
cessing the mouth of a cytosolic vestibule. This will be the sub-
ject of future experiments.
Previous experiments that identified residues 562–679 as
essential for the functional effect of XIP (Maack et al., 2005) are
not inconsistent with our finding that XIP binds elsewhere in
the f-loop. Indeed, the fact that a functionally inactive XIP pep-
tide affinity purifiedWTNCX1 equally as well asWT XIP suggeststhat XIP binding to and inactivation of
NCX1 occur independently. The important
implications of this observation are that
experimental and therapeutic strategies
to inhibit XIP activity must target a different
region of the f-loop than those aiming to
mimic XIP activity. The region of the
f-loop required for XIP efficacy is likely
smaller than has been defined to date,but it was beyond the scope of the current investigation to
fine-map its location.
The fact that we were able to achieve modest co-purification
of unpalmitoylatable NCX1 with XIP suggests that a low-affinity
interaction with XIP is maintained when NCX1 is not palmitoy-
lated. In keeping with this, exogenous XIP slightly increases
the FRET activity of unpalmitoylatable NCX1, implying that it re-
tains some ability to regulate unpalmitoylated NCX1. This is
consistent with our earlier finding that NCX1 shows reduced
(but not entirely absent) inactivation when unpalmitoylated (Reilly
et al., 2015) and implies that even when binding of XIP to its
docking site is reduced (whenNCX1 is not palmitoylated), a func-
tional effect on NCX1 can be achieved.
NCX1-NCX1 FRET
It has previously been shown in Xenopus plasma membrane
sheets that NCX1-NCX1 FRET increases dynamically as Ca oc-
cupies the CBDs (John et al., 2011). Multiple structural rear-
rangements leading to altered NCX1-NCX1 FRET are evidently
possible, some of which are independent of palmitoylation. Pal-
mitoylation-induced changes in NCX1-NCX1 FRET only occurCell Reports 31, 107697, June 9, 2020 9
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Figure 6. NCX1 Relationship with zDHHC5
(A) An array of biotinylated zDHHC5 peptides rep-
resenting the zDHHC5 C tail affinity purifies NCX1
from rat ventricular lysates.
(B) NCX1 palmitoylation is increased by co-
expression of WT, but not catalytically inactive
zDHHC5, in zDHHC5 KO cells. ***p = 0.0002
(knockout [KO] versus +zDHHC5), 0.0009 (+DHHC5
versus zDHHS5), calculated by unpaired t test,
N = 4.
(C) NCX1-NCX1 FRET recordings in HEK and
zDHHC5 KO cells.
(D) NCX1-NCX1 FRET is reduced in zDHHC5 KO
cells and is no longer sensitive to changes in
extracellular ion concentrations. ****p < 0.0001, *p =
0.01, calculated by unpaired t test. N = 14 (WT,
Tyrode’s), 18 (WT, Ca-free), 16 (DHHC5 KO
Tyrode’s), and 20 (DHHC5 KO, Ca-free),
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OPEN ACCESSwhen lipid rafts can form (discussed below), which suggests that
there is a requirement for particular phospholipid(s) and/or the
membrane’s physical properties to support palmitoylation-
induced restructuring of the NCX1 dimer. We propose that the
‘‘palmitoylated-high FRET form’’ of NCX1 identified in this inves-
tigation represents a species that can inactivate, while the ‘‘un-
palmitoylated-low FRET form’’ is less capable of inactivating,
because it has a lower affinity for XIP. Our finding that Ca-free
conditions enhance both NCX1 palmitoylation and FRET are
important, because this suggests that Na binding to its allosteric
regulatory site, already established to promote NCX1 inactiva-
tion, may trigger a positive feedback loop to inactivate NCX1
by enhancing its palmitoylation, sensitizing NCX1 XIP. Although
the location of the allosteric regulatory site for Na is as-yet un-
known, it does not lie within the CBDs (Boyman et al., 2009,
2011). The possibility that this site is close to the palmitoylation
site in NCX1 should now be considered.
Dynamic NCX1 Palmitoylation at the Cell Surface
We have previously identified the Golgi as the principal site of
NCX1 palmitoylation, because a YFP fusion protein that includes
theNCX1palmitoylationsite (but not the transmembranedomains)
becomes trapped in the Golgi apparatus (Plain et al., 2017; Reilly
et al., 2015). Here, we extend these findings and report that
following itsdelivery to thecell surface,NCX1 isdynamicallydepal-
mitoylated and repalmitoylated by APT1 and zDHHC5, respec-
tively. The localization of a palmitoylated NCX1 f-loop to the Golgi
suggests that the Golgi-localized NCX1 zDHHC-PAT is a higher-
capacity palmitoylation system than zDHHC5, which is consistent
with theGolgi beingamajor cellular ‘‘hub’’ of protein palmitoylation
(Ernst et al., 2018; Salaun et al., 2010). Alternatively, palmitoylation10 Cell Reports 31, 107697, June 9, 2020of NCX1 by zDHHC5may require the NCX1
transmembrane domains to be present.
Regardless of this, however, our observa-
tions suggest that following its delivery to
the cell surface, cellular mechanisms exist
to dynamically modify the sensitivity of
NCX1 to inactivation via changes to its pal-
mitoylation status, as brought about byAPT1 and zDHHC5. Substrate ‘‘recognition rules’’ for thioesterase
enzymes remain largely uninvestigated. Our experiments here
show that the amphipathic a-helix that is required for NCX1 palmi-
toylation isalso recognizedbyAPT1.Recruitment of zDHHC-PATs
and thioesterases to NCX1 may not, therefore, be independent
events.
Little information exists about the regulatory events that control
substrate palmitoylation and depalmitoylation, although palmitoy-
lation cascades (Abrami et al., 2017) and phosphorylation-depen-
dent substrate palmitoylation (Brigidi et al., 2015) have both been
reported in recent years. In this study, we have identified one
cellular event that regulates NCX1 palmitoylation by zDHHC5,
ion binding site occupancy, which restructures the NCX1 f-loop
to alter the ability of zDHHC5 to palmitoylate NCX1. It is likely
that other mechanisms that remain to be identified regulate
NCX1 palmitoylation at the cell surface. Indeed, our finding that
NCX1 palmitoylation is not entirely abolished in zDHHC5 KO cells
implies that other zDHHC-PATs, possibly both in the secretory
pathway and at the cell surface, also regulate NCX1.
Palmitoylation and the Microdomain Localization
of NCX1
This investigation is the first report that demonstrates that a
multi-pass membrane domain protein can have significant affin-
ity for the ordered phase of phase-separated GPMVs. The
concept that lipid-lipid interactions lead to the dynamic forma-
tion of lipid rafts in live cells (Simons and Ikonen, 1997) is not uni-
versally accepted (Douglass and Vale, 2005; Munro, 2003). This
investigation provides direct support for the concept that such
rafts exist in intact cells. This is because palmitoylation modifies
the FRET behavior of NCX1 dimers only when rafts are able to
AB
Figure 7. Impact of NCX1 Palmitoylation on Intracellular Ca
(A) Steady-state intracellular Ca was evaluated using the fluorescent indicator
Fluo 4 based on measured fluorescence intensity in the cells. Fluorescence
intensity in FT-293 cells expressing WT NCX1 is lower than in FT-293 cells
expressing unpalmitoylatable NCX1 (C739A) (WT: 158.69 ± 1.44, C739A:
169.64 ± 1.10). Data in each panel are presented as scattered individual
data points with standard error, boxplot with median and half violin plot.
****p < 0.0001, calculated by unpaired t test. N = 855 (WT NCX1) and 915
(C739A). Scale bar, 20 mm.
(B) Elevating NCX1 palmitoylation with the thioesterase inhibitor PalmB
reduced intracellular Ca signals in cells expressing WT NCX1, whereas the
APT2 inhibitor ML349 is without effect (DMSO, 143.51 ± 1.49; PalmB, 124.98 ±
1.11; ML349, 140.12 ± 1.79). ****p < 0.0001, calculated by unpaired t test.
N = 991 (DMSO), 901 (PalmB), and 642 (ML349).
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the FRET activity of WT NCX1 to match that of unpalmitoylatable
NCX1, whereas the FRET activity of unpalmitoylatable NCX1
was insensitive to the manipulation of the membrane. The
cholesterol-dependent and independent clustering of peripheral
(Zhou and Hancock, 2015) and single-pass integral (Lorent et al.,
2017) membrane proteins into microdomains of unique lipidcomposition is well established. The palmitoylation of H-Ras,
for example, controls its affinity for lipid ordered domains and en-
hances H-Ras clustering in these domains (Janosi et al., 2012).
We propose that a similar relationship exists for NCX1; palmitoy-
lation changes the affinity of NCX1 for a microdomain in the sur-
face membrane and promotes NCX1-NCX1 FRET in this
microdomain.
Our results show that the presence of WT, but not unpalmitoy-
latable, NCX1 impaired the phase separation of GPMVs. The
simplest explanation for this phenomenon is that the tempera-
ture at which phase separation occurs is decreased by the pres-
ence of WT (but not unpalmitoylatable) NCX1. This impact of WT
NCX1 on GPMV phase separation suggests that the presence of
a palmitoylated protein can significantly alter the behavior of the
lipids with which it interacts and is another example of the dy-
namic palmitoylation of an integral membrane protein profoundly
changing the behavior of its phospholipid environment (Fuller
et al., 2016; Hilgemann et al., 2013, 2019; Reilly et al., 2015).
We suggest that the ability of NCX1 to bind PIP2 via its XIP
domain establishes a scenario in which the attraction of palmi-
toylated NCX1 to lipid-ordered domains ‘‘conflicts’’ with the
binding of PIP2 elsewhere in the protein. This is strikingly similar
to the behavior of palmitoylated and farnesylated H-Ras in mo-
lecular dynamics simulations. The presence of saturated palmi-
tate attracts H-Ras to the lipid ordered phase, and the presence
of unsaturated farnesyl attracts it to the disordered phase, result-
ing in the clustering of such dually lipidated proteins at order/dis-
order boundaries (Janosi et al., 2012).
Concluding Remarks
We identify a small region of the NCX1 f-loop that is required for
XIP binding that is distinct from the region of the f-loop required
for XIP function. We report that the dynamic regulation of NCX1
palmitoylation at the cell surface controls its ability to inactivate
(by modifying the interaction between XIP and its binding site)
and affinity for lipid microdomains. The modified XIP sensitivity
ultimately facilitates palmitoylation-dependent control of
NCX1-mediated transmembrane Ca flux and hence cytosolic
Ca levels. Given the importance of inactivation in controlling
NCX1-mediated Ca influx, future research to identify the path-
ways that control NCX1 palmitoylation could enable the inactiva-
tion of this ubiquitous ion transporter to be manipulated.
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OPEN ACCESSSTAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
NCX1 SWANT Cat#R3F1; RRID:AB_2716744
FLOT2 BD Biosciences Cat#610384; RRID:AB_397767
DHHC5 Sigma Cat#HPA014670; RRID:AB_2257442
GFP Abcam Cat#ab32146; RRID:AB_732717
Chemicals, Peptides, and Recombinant Proteins
NCX1 peptide (NCX1740-756) with N-terminal biotin Alta Biosciences N/A
DHHC5 peptides (C-tail: DHHC5213-237,223-247,233-257,243-267,253-
277,263-287,273-297,283-307,293-317,303-327,313-337,323-347,333-357)
all with N-terminal biotin
Alta Biosciences N/A
XIP (WT and K229Q XIP; NCX1219-238) with N-terminal biotin Alta Biosciences N/A
PalmB Calbiochem Cat#178501
ML348 Dr. Brent Martin, University of MichiganN/A
ML349 Dr. Brent Martin, University of MichiganN/A
Filipin Sigma Cat#F9765
Ctx Alexa Fluor 647 Invitrogen Cat#C34778
FAST-Dil Invitrogen Cat#D7756
Palmitic Acid Sigma Cat#0500
2-Bromopalmitate Sigma Cat#238422
Methyl-b-cyclodextrin Sigma Cat#332615
Critical Commercial Assays
Fluo-4 Direct Calcium Imaging Invitrogen Cat#F10472
Experimental Models: Cell Lines
FT-293 Invitrogen Cat#R70007
HEK293T ATCC CRL-1573
Experimental Models: Organisms/Strains
New Zealand White Rabbit Envigo 444
Sprague Dawley Rat Envigo 002
Oligonucleotides
NCX1 D709-728 cloning, forward: 50-GGACAAACGATGAA
TGTGGAGAGGAGAAGC-30
Eurofins Genomics N/A
NCX1 D709-728 cloning, reverse: 50-ATTCATCGTTTGTCC
CAACCACAAGGGC-30
Eurofins Genomics N/A
C739A NCX1 mutagenesis, forward: 50-TGCATCAC
ATAATCGAAAGCGGAGGGCAGCTTCTCCTC-30
Eurofins Genomics N/A
C739A NCX1 mutagenesis, reverse: 50-GAGGAGAAG
CTGCCCTCCGCTTTCGATTATGTGATGCA-3
Eurofins Genomics N/A
Recombinant DNA
Canine NCX1.1 cDNA Kenneth Philipson, UCLA N/A
Canine NCX1.1 with CFP or YFP inserted at amino acid 266 Michela Ottolia, UCLA N/A
YFP fusion proteins to the N terminus the NCX1.1 intracellular loopReilly et al., 2015;
Plain et al., 2017
N/A
Software and Algorithms
GraphPad Graphpad Prism v6 https://graphpad.com
ImageJ / Fiji Schindelin et al., 2012 https://imagej.nih.gov/ij/
The Discovery Series Quantity One 1-D Analysis Software
Version 4.6.6, PC
Bio-Rad LIT-70-9600-Q1-466PC
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Lead Contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, William
Fuller (will.fuller@glasgow.ac.uk).
Materials Availability
Plasmids and cell lines generated in this study are available from the Lead Contact.
Data and Code Availability
The published article includes all datasets generated or analyzed during this study.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Ethics
This study utilized primary cells from rats and rabbits. All protocols involving animals were approved by the University of Glasgow
Animal Welfare and Ethics Review Board. Rat cardiac and brain tissues were collected post-mortem after sacrificing animals using
amethod designated Schedule 1 by the Animals (Scientific Procedures) Act 1986. Rabbit hearts were excised from terminally anaes-
thetized, heparin-treated animals under the authority of a Project License granted by the UK Home Office.
Immortalized Cell Lines and Plasmids
HEK293 cells, HEK293 derived FT293 cell expressing tet-inducible wild-type (WT)-NCX1 and C739A-NCX1 and DHHC5 KO cells
were used in this investigation. HEK293 derived FT293 cell expressing tet-inducible wild-type (WT)-NCX1 and C739A-NCX1 were
generated using the Invitrogen Flip-In T-Rex System (Reilly et al., 2015).
NCX1 FRET sensors with either CFP or YFP inserted at position 266 (John et al., 2011) were a kind gift from Prof Michela Ottolia
(UCLA, USA). Position 739 in the NCX1 f-loop of both YFP and CFP sensors was mutated from Cysteine to Alanine using the
Quikchange Lightning Site-Directed Mutagenesis kit (Agilent). YFP fusions to the NCX1 f-loop are described elsewhere (Plain
et al., 2017). YFP-NCX1 D709-728 was generated using InFusion (Takara) cloning. Plasmid constructs were transfected using
Lipofectamine2000 (Invitrogen) for HEK293 cell and Lipofectamine LTX (Invitrogen) for neonatal myocytes, according to the manu-
facturer’s instructions. Full details of all plasmids and the oligonucleotides used to generate them are provided in the Key Resources
Table.
Generation of zDHHC5 knockout cells
We evaluated guide RNAs (gRNA) targeted against zDHHC5 provided by Horizon Discovery (Cambridge, UK). The selected gRNA
targets 57,673,152 to 57,673,171 of Homo sapiens chromosome 11, and demonstrated a 46% targeting efficiency in a genome
cleavage detection assay (ThermoFisher Scientific). gRNA was inserted into vector pEsgRNA into which a puromycin resistance
cassette had been added (Munoz et al., 2014), which was transfected into FT-293 cells expressing tet-inducible cas9. After the in-
duction of cas9 and following selection with puromycin (3mg/ml), cells were sorted to one cell per well in 96 well plates. Genomic DNA
was isolated after clone expansion, amplified with primers directed against DHHC5 exon 2 (CCCATGTGCTTTCCTTCATT forward
and CAGCCTGAGTGACAGAGCAA reverse), and sequenced. Seven out of 25 clones sequenced had no detectable wild-type
DHHC5 alleles; the clone selected had an additional 388 bases inserted at position 57,673,154 of chromosome 11. Cas9 was
removed from this clone by transfection with pOG44 Flp-Recombinase, and cells were selected and maintained in the presence
of zeocin.
Ventricular Myocytes and Cardiac Tissue
Neonatal ventricular myocytes (NRVMs) were isolated fromWistar rat pups of mixed sex between postnatal day 1-4 using 0.45mg/ml
Collagenase (Roche) and 1.25mg/ml Pancreatin (Sigma) in ADS buffer (106mM NaCl, 20mM HEPES, 800mM NaH2PO4, 5mM KCl,
400mM MgSO4, 5mM Glucose; pH: 7.4) as digestion solution. The ventricles were cut into pieces and digested in a shaking water
bath at 37C. Cell suspension was collected every 20min and each time fresh digestion solution was added to the undigested tissue.
Collected cells were plated in 10cm cell culture dishes for 2h to allow fibroblasts to attach to the bottom (pre-plating), then transferred
to either EHS-Laminin coated glass coverslips to be used for FRET imaging or gelatin coated wellplates. Cells were incubated under
standard cell culture conditions at 37C and 5% CO2 in Day-1 Medium (Dulbecco’s Modified Eagle Medium (DMEM6171, GIBCO),
Medium199 (M-199, GIBCO), 10% Horse Serum, 5% NCS, 1%Glutamine and 1% Pen-Strep). After 24h incubation, the culture me-
dium was replaced with Day-2 Medium containing low serum (5% Horse Serum and 0.5% NCS).
Calcium-tolerant adult rabbit ventricular myocytes were isolated from the left ventricular free wall of male New Zealand White rab-
bits (2.8-3.2kg, 14-19wks) following perfusion with collagenase in the Langendorff mode, as described previously (Kettlewell et al.,
2009).Cell Reports 31, 107697, June 9, 2020 e2
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with dry ice after harvesting.
METHOD DETAILS
Drugs and Reagents
APT inhibitors Palmostatin B (PalmB), ML348 and ML349, Palmitic Acid (PA) and 2-Bromopalmitate (2BP) were investigated in this
study. PalmB, PA and 2BP were purchased from Sigma. ML348 andML349 were generously provided by Dr Brent Martin, University
of Michigan, USA. All compounds were dissolved in DMSO and comparisons made to an appropriate vehicle control.
Purification of palmitoylated proteins
Palmitoylated proteins were purified by resin-assisted capture of acylated proteins (acyl-RAC) following blockade of free cysteines
with MMTS and cleavage of thioester bonds with neutral hydroxylamine, as described in detail elsewhere (Plain et al., 2017). Palmi-
toylation of NCX1 is expressed as the amount purified by the acyl-RAC reaction relative to its abundance in the corresponding un-
fractionated cell lysate.
Protein Cross-linking
NCX1 cross-linking was carried out using the cysteine-reactive homobifunctional crosslinker bismaleimidohexane (BMH). Cross-
linking buffer (with final concentration 0.1mM BMH) was 10mM Tris-HCl at pH: 7.2 and 150mM NaCl. FT-293 cells expressing tetra-
cycline-inducible NCX1 were plated on poly-l-lysine (PLL, Sigma) coated 6 well plates. Following 3 washes with cross-linking buffer
without BMH, cells were treated with 0.1mM BMH for 5min at 37C. After cross-linking, cells were washed 3 times and proteins sol-
ubilized for 30min at 4C in lysis buffer with 1% Triton X-100 and protease inhibitors. Solubilized cell lysate were centrifuged at
17500 g for 5min to eliminate insoluble material before analyzing by SDS-PAGE.
FRET Imaging
FRET experiments were performed on NRVMs and HEK293 cells 24-48h after transfection with NCX1 FRET sensors. Cells were
maintained in Tyrode’s buffer (120mM NaCl, 5mM KCl, 1mMMgCl2, 1.8mM CaCl2 and 10mM HEPES; pH:7.4) at room temperature
while FRET signals were recorded, unless an experiment is indicated as being either Calcium-free (CaF: 120mM NaCl, 5mM KCl,
1mM MgCl2, 1mM EGTA and 10mM HEPES; pH:7.4) or Sodium-free (NaF: 120mM NMDG
+, 5mM KCl, 1mM MgCl2, 1.8mM CaCl2
and 10mM HEPES; pH:7.4). FRET activity was imaged by an inverted camera; Olympus 1X71, with PlanApon, 60X, NA 1.42 oil im-
mersion objective, 0.17/FN 26.5 (Olympus, UK). The microscope was equipped with a CCD camera (cool SNAP HQ Monochrome,
Photometrics) and a beam splitter optical device (Dual-channel simultaneous imaging system, DV2 mag biosystem (ET-04-EM).
MetaFluor 7.1 (Meta imaging system) was used for image acquisition and analysis. FRET ratio was measured as the changes in
the background subtracted 480/545nm fluorescent emission intensity on excitation at 430nm.
Giant Plasma Membrane Vesicles (GPMV)
GPMVs were formed and analyzed as described previously (Sezgin et al., 2012). Briefly, HEK293 cells were plated onto poly-L-lysine
(PLL, Sigma) coated 35mm dishes and transfected with CFP-tagged NCX1. After 24h, cells were washed twice with GPMV buffer
(150mM NaCl, 2mM CaCl2 and 10mM HEPES, pH: 7.4). GPMVs were formed using vesiculation buffer (25mM PFA, 2mM DTT,
0.001% Deoxycholate in GPMV buffer) for 1h at 37C. The presence of DTT in the vesiculation buffer did not alter the palmitoylation
status of NCX1 or flotillin 2 (Figure S1). The vesiculation buffer was supplemented with deoxycholate to improve phase separation
(Zhou et al., 2013). Vesicles were visualized as free-floating dark spheres at the plane of the cells at 20X magnification. GPMV-rich
cellular supernatant was harvested and transferred to centrifuge tubes and left to settle. GPMVs were labeled using FAST-DIL (5mg/
ml, Invitrogen-D7756) for non-raft phaseandCTxB-AlexaFluor647 (5mg/ml, Invitrogen-C34778) for raft phase,and imagedonacustom-
ised imaging chamber. GPMVs were imaged using a Zeiss LSM880 with Airyscan confocal microscopy. Diode (405-430nm), Argon
(458nm,488nm, 514nm) andHeNe633 (633nm) laserswere used for the excitation of blue (NCX1-CFP), green (FAST-DIL) and red (Alex-
aFluor647). The colocalization of NCX1 with lipid phases was analyzed using Coloc2 macro in Fiji (Schindelin et al., 2012).
Manipulating Cholesterol in Intact Cells
The manipulation of cholesterol in cells was achieved by using either MbCD (Sigma) to deplete cholesterol or SDS (Sigma) to force
microdomain formation. Cholesterol was depleted as described previously (Eshcol et al., 2008; Qi et al., 2015): HEK293 cells were
washed three times with PBS, then incubated with 5mMMbCD for 30min at 37C. HEK293 cells were treated with 25mMSDS at 37C
for 15min to facilitate/increase microdomain formation. Following either MbCD or SDS incubation, cholesterol was detected with
Filipin (50mg/ml in PBS, Sigma) as described (Qi et al., 2015) after fixation with 4% PFA for 10min at room temperature.
Peptide Affinity Purification and LC-MS/MS
Peptides with N-terminal biotin tags were synthesized by Alta Bioscience (Birmingham, UK). For affinity purification reactions, 20-
50mg frozen powdered rat brain or heart tissue was lysed in 500ml lysis buffer (2mg/ml C12E10 in PBS supplemented with proteasee3 Cell Reports 31, 107697, June 9, 2020
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tants were applied to pre-equilibrated Streptavidin-Sepharose beads to preclear for 1h at 4C, then incubated with 3mM biotinylated
peptides overnight at 4C. The next day, pre-equilibrated Streptavidin-Sepharose beads were added to the lysate-peptide mix and
incubated for 3h at 4C. The beads were washed 5 times with lysis buffer and interacting proteins were eluted in one of two ways. For
the LC-MS/MS identification of NCX1-interacting proteins, beads were incubated with lysis buffer supplemented with 10mM
NCX1740-756 peptide and 1mM biotin for 1h at 4C. After elution, the beads were washed once more with lysis buffer and the remain-
ing proteins eluted with 2X LDS PAGE buffer supplemented with 100mM DTT. NCX1 interacting proteins were visualized by SDS-
PAGE, stained with Coomassie, and identified using LC-MS/MS with a LTQ Orbitrap Velos Pro (Thermo) at the FingerPrints prote-
omics facility, University of Dundee.
Proteins interacting with biotinylated zDHHC5 and XIP peptides were eluted using 2x SDS-PAGE loading buffer and analyzed by
western blot. Sequences of the custom-made peptides are provided in the Key Resources Table.
Intracellular Calcium Imaging
Intracellular calcium levels were monitored using the fluorescent calcium indicator Fluo4-Direct (Invitrogen) according to manufac-
turer’s instructions. Tet-inducible stable cell lines (wild-type; WT NCX1 and unpalmitoylatable; C739A) were cultured on poly-l-lysine
(PLL, Sigma) coated 35mm glass bottom dishes (MatTek Life Sciences). 16-24h after inducing NCX1 expression with tetracycline
(1mg/ml), cells were loaded with Fluo4 for 1h at 37C. Calcium indicator loaded cells were imaged using a Zeiss LSM8800 with
Airyscan confocal microscopy (lexcitation = 494 nm, lemission = 520 nm).
QUANTIFICATION AND STATISTICAL ANALYSIS
All data are presented as mean ± standard error of the mean. Quantitative differences between groups were assessed using One-
way ANOVA analysis followed by appropriate post hoc t tests using GraphPad Prism. Intracellular calcium imaging data was eval-
uated and presented using Raincloud plots (Allen et al., 2019). The values of p and N are provided in individual figure legendsCell Reports 31, 107697, June 9, 2020 e4
